Lapatinib Ditosylate - CAS 388082-77-7
Catalog number:
388082-77-7
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C29H26ClFN4O4S.2C7H8O3S
Molecular Weight:
925.46
COA:
Inquire
Targets:
EGFR
Description:
Lapatinib is a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
GW-572016
MSDS:
Inquire
1.Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
Awada A1, Colomer R2, Inoue K3, Bondarenko I4, Badwe RA5, Demetriou G6, Lee SC7, Mehta AO8, Kim SB9, Bachelot T10, Goswami C11, Deo S12, Bose R13, Wong A14, Xu F14, Yao B14, Bryce R14, Carey LA15. JAMA Oncol. 2016 Apr 14. doi: 10.1001/jamaoncol.2016.0237. [Epub ahead of print]
Importance: Efficacious ERBB2 (formerly HER2 or HER2/neu)-directed treatments, in addition to trastuzumab and lapatinib, are needed.
2.Characterization of the binding of an anticancer drug, lapatinib to human serum albumin.
Kabir MZ1, Mukarram AK2, Mohamad SB3, Alias Z1, Tayyab S4. J Photochem Photobiol B. 2016 Apr 13;160:229-239. doi: 10.1016/j.jphotobiol.2016.04.005. [Epub ahead of print]
Interaction of a promising anticancer drug, lapatinib (LAP) with the major transport protein in human blood circulation, human serum albumin (HSA) was investigated using fluorescence and circular dichroism (CD) spectroscopy as well as molecular docking analysis. LAP-HSA complex formation was evident from the involvement of static quenching mechanism, as revealed by the fluorescence quenching data analysis. The binding constant, Ka value in the range of 1.49-1.01×105M-1, obtained at three different temperatures was suggestive of the intermediate binding affinity between LAP and HSA. Thermodynamic analysis of the binding data (∆H=-9.75kJmol-1 and ∆S=+65.21Jmol-1K-1) suggested involvement of both hydrophobic interactions and hydrogen bonding in LAP-HSA interaction, which were in line with the molecular docking results. LAP binding to HSA led to the secondary and the tertiary structural alterations in the protein as evident from the far-UV and the near-UV CD spectral analysis, respectively.
3.Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
Hernandez SF1, Chisholm S2, Borger D3, Foster R4, Rueda BR4, Growdon WB5. Gynecol Oncol. 2016 Apr 1. pii: S0090-8258(16)30083-X. doi: 10.1016/j.ygyno.2016.03.027. [Epub ahead of print]
OBJECTIVE: Uterine serous carcinomas (USC) harbor simultaneous HER2 (ERBB2) over-expression and gain of function mutations in PIK3CA. These concurrent alterations may uncouple single agent anti-HER2 therapeutic efficacy making inhibition of the mammalian target of rapamycin (mTOR) a promising option to heighten anti-tumor response.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related EGFR Products


CAS 1110813-31-4 Dacomitinib

Dacomitinib
(CAS: 1110813-31-4)

Dacomitinib, aslo known as PF-299 and PF-00299804; or PF299804, is an orally bioavailable, highly selective, second-generation small-molecule inhibitor of the p...

EGF816
(CAS: 1508250-71-2)

EGF816, also called as Nazartinib, a covalent mutant-selective EGFR inhibitor and potently inhibits the T790M resistance mutation while sparing wild-type EGFR. ...

CAS 171179-06-9 PD158780

PD158780
(CAS: 171179-06-9)

PD158780 is a potent, cell-permeable, reversible ATP-competitive inhibitor of EGFR tyrosine kinase activity with IC50 values of 0.008, 49 and 52 nM for EGFR, Er...

CAS 183321-74-6 Erlotinib

Erlotinib
(CAS: 183321-74-6)

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

CAS 698387-09-6 Neratinib

Neratinib
(CAS: 698387-09-6)

Neratinib, also known as HKI-272 or PB272, is an orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile irreversible inhibitor of the HER-2 recep...

NT113
(CAS: 1398833-56-1)

NT113 is a pan-ERBB inhibitor with high brain penetrance. It can inhibit the growth of glioblastoma xenografts with EGFR amplification. NT113 is active against ...

CAS 848942-61-0 AZD-8931

AZD-8931
(CAS: 848942-61-0)

Sapitinib, also known as AZD-8931, is an erbB receptor tyrosine kinase inhibitor with potential antineoplastic activity. AZD8931 binds to and inhibits erbB tyro...

Naquotinib mesylate
(CAS: 1448237-05-5)

Naquotinib is irreversible, third-generation, epidermal growth factor receptor (EGFR) inhibitor with IC50 value of 70 nM for NCI-H1650 cell growth. It can coval...

CAS 937265-83-3 ARRY-380

ARRY-380
(CAS: 937265-83-3)

ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR.

MTX-211
(CAS: 1952236-05-3)

MTX-211 is a dual inhibitor of EGFR and PI3K, which plays important roles in the progression of KRAS mutant colorectal cancer. MTX-211 has the potential for the...

CAS 937263-43-9 Irbinitinib

Irbinitinib
(CAS: 937263-43-9)

Irbinitinib,also known as ARRY-380 and ONT-380, is an orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also...

CAS 1421373-65-0 AZD-9291

AZD-9291
(CAS: 1421373-65-0)

AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become ...

CAS 451492-95-8 MP-412

MP-412
(CAS: 451492-95-8)

MP-412 (AV-412) is a second-generation, orally bioavailable dual kinase inhibitor with potential antineoplastic activity. EGFR/HER2 inhibitor AV-412 binds to an...

CAS 1214265-57-2 WZ-8040

WZ-8040
(CAS: 1214265-57-2)

WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor with potential anticancer activity. WZ8040 is about 30-fold more potent against EGFR T790M, ...

Anlotinib
(CAS: 1058156-90-3)

Anlotibib is a multi-targetes kinase inhibitor of receptor tyrosine and could effectively resist the formation of new angiogenesis and is under Phase III trail ...

CAS 257933-82-7 Pelitinib

Pelitinib
(CAS: 257933-82-7)

Pelitinib is a 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity. EKB-569 irreversibly binds covalently to epidermal gr...

CAS 1204313-51-8 Icotinib (Hydrochloride)

Icotinib (Hydrochloride)
(CAS: 1204313-51-8)

CAS 136831-48-6 RG13022

RG13022
(CAS: 136831-48-6)

RG13022, a non-phenolic tyrphostin analog, is an epidermal growth factor (EGF) receptor tyrosine kinase inhibitor with potential antiproliferative effect.

CAS 1214265-56-1 WZ-3146

WZ-3146
(CAS: 1214265-56-1)

WZ-3146 is an irreversiblely inhibitor against EGFR T790M with potential anticancer activity.

CAS 383432-38-0 CP-724714

CP-724714
(CAS: 383432-38-0)

CP-724714 is An orally bioavailable quinazoline with potential antineoplastic activity. CP-724,714 selectively binds to the intracellular domain of HER2, revers...

Chemical Structure

CAS 388082-77-7 Lapatinib Ditosylate

Quick Inquiry

Verification code

Featured Items